SCHEMBL648559

SCHEMBL648559

O=C1N/C(=N/Cc2cccc(Cl)c2Cl)S/C1=C\c1cnc(NC(=O)C2CC2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
LCK P06239 2/20 0.39
MAPK13 O15264 1/20 0.39
EGFR P00533 1/20 0.39
FYN P06241 1/20 0.39
HCK P08631 1/20 0.39
SRC P12931 1/20 0.39
JAK3 P52333 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
LMNA P02545 2/20 0.38
LIMK1 P53667 1/20 0.38
LIMK2 P53671 1/20 0.38
PTPN1 P18031 2/20 0.37
CDC25B P30305 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651957 0.93 LMNA (0.41) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL650973 0.87 LMNA (0.39) SMN1; SMN2RAB9AKMT2AMEN1LCK
SCHEMBL651064 0.86 PIM1 (0.47) NPC1RAB9AKMT2AJAK3LMNA
SCHEMBL10176414 0.85 HPGD (0.53) JAK3PTPN1CDC25BHPGDPKM
SCHEMBL649937 0.83 MEN1 (0.43) KMT2AMEN1LMNALIMK1PTPN1
SCHEMBL649936 0.83 MEN1 (0.43) KMT2AMEN1LMNALIMK1PTPN1
SCHEMBL651311 0.83 PTPN1 (0.41) SMN1; SMN2LIMK1LIMK2PTPN1CDC25B
SCHEMBL651355 0.82 PTPN1 (0.46) KMT2AMEN1JAK3LMNAPTPN1
SCHEMBL10176413 0.80 PTPN1 (0.44) PTPN1CDC25BHPGDPKMPOLB
SCHEMBL10176412 0.80 GSK3B (0.47) NPC1RAB9AKMT2APTPN1CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 SMN1; SMN2 4601/4885NPC1 1074/4885RAB9A 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.